Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CARMINA, Enrico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.990
EU - Europa 1.809
AS - Asia 781
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 8
SA - Sud America 7
OC - Oceania 4
Totale 7.620
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.982
IT - Italia 507
UA - Ucraina 413
CN - Cina 366
FI - Finlandia 272
SG - Singapore 269
IE - Irlanda 156
DE - Germania 123
GB - Regno Unito 120
KR - Corea 68
RU - Federazione Russa 60
SE - Svezia 52
FR - Francia 35
TR - Turchia 23
CI - Costa d'Avorio 20
RO - Romania 18
BE - Belgio 17
IN - India 17
IR - Iran 9
EU - Europa 8
HK - Hong Kong 8
NL - Olanda 8
CA - Canada 6
AT - Austria 5
BR - Brasile 5
CH - Svizzera 5
JP - Giappone 4
PL - Polonia 4
AU - Australia 3
IQ - Iraq 3
PH - Filippine 3
BG - Bulgaria 2
LT - Lituania 2
MX - Messico 2
PK - Pakistan 2
PT - Portogallo 2
RS - Serbia 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AM - Armenia 1
CL - Cile 1
DK - Danimarca 1
ES - Italia 1
GR - Grecia 1
ID - Indonesia 1
MA - Marocco 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
VE - Venezuela 1
Totale 7.620
Salva come PNG Salva come JPEG
Città #
Fairfield 793
Ashburn 486
Woodbridge 421
Chandler 364
Houston 359
Seattle 329
Wilmington 291
Cambridge 259
Singapore 225
Jacksonville 224
Ann Arbor 190
Palermo 171
Dublin 154
Medford 120
Nanjing 82
Princeton 77
Altamura 75
Lawrence 62
Tulsa 62
Dearborn 59
San Diego 50
Seongnam 50
Boardman 46
Santa Clara 39
Shenyang 32
Beijing 29
Nanchang 28
Milan 26
New York 25
Hebei 23
Izmir 23
Jiaxing 21
Abidjan 20
Changsha 19
Des Moines 18
Jinan 17
Zhengzhou 17
Brussels 16
San Paolo di Civitate 16
Columbus 14
London 14
Saint Petersburg 14
Ludwigshafen am Rhein 13
Tianjin 13
Auburn Hills 12
Guangzhou 12
Helsinki 11
Verona 11
Los Angeles 10
Seoul 10
Falls Church 9
Ningbo 9
Redwood City 9
Kilburn 8
Kumar 8
Taizhou 8
Lanzhou 7
Redmond 7
Orange 6
Taiyuan 6
Düsseldorf 5
San Mateo 5
Bangalore 4
Chicago 4
Haikou 4
Hefei 4
Norwalk 4
Ottawa 4
Andover 3
Frankfurt am Main 3
Hangzhou 3
Hong Kong 3
Leander 3
Menlo Park 3
Moscow 3
Munich 3
Shanghai 3
Tehran 3
Timisoara 3
Tokyo 3
Wanchai 3
Alwar 2
Belgrade 2
Bremen 2
Central District 2
Chiswick 2
Den Haag 2
Ensenada 2
Kiev 2
Kraków 2
Kunming 2
Messina 2
Montreal 2
Multan 2
Mumbai 2
Phoenix 2
Pontedera 2
Sacramento 2
Saint Louis 2
San Jose 2
Totale 5.640
Salva come PNG Salva come JPEG
Nome #
High prevalence of polycystic ovary syndrome in women with mild hirsutism and no other significant clinical symptoms 250
Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. 171
Hypogonadism and hormone replacement therapy on bone mass of Adult Women with Thalassemia Major 156
Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis 149
Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome 145
Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in Southern Italy than in USA and the influence of criteria for the diagnosis of PCOS 142
Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. 142
Does the level of serum antimüllerian hormone predict ovulatory function in women with polycystic ovary syndrome with aging? 139
OVARIAN AND ADRENAL HYPERANDROGENISM 135
The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report 134
Prospective parallel randomized double-blind double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first line treatment for ovulation induction in non-obese anovulatory women with polycystic ovary syndrome 131
Consensus on women's health aspects of polycystic ovary syndrome (PCOS) 131
Reproductive outcome of women with 21-hydroxylase deficient non-classic adrenal hyperplasia 131
Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome 129
A 20-year follow-up of young women with Polycystic Ovary Syndrome 128
Diagnosis, Phenotype and Prevalence of Polycystic Ovary Syndrome 126
PHENOTYPIC VARIATION IN HYPERANDROGENIC WOMEN INFLUENCES THE FINDINGS OF ABNORMAL METABOLIC AND CARDIOVASCULAR RISK PARAMETERS. 122
Cardiovascular risk and events in polycystic ovary syndrome 122
Influence of sociocultural factors on the ovulatory status of polycystic ovary syndrome. 121
Lifecycle of Polycystic Ovary Syndrome (PCOS): From In Utero to Menopause 121
Insulin resistance in postmenopausal women with metabolic syndrome and the measurements of adiponectin, leptin, resistin and ghrelin 120
Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society 120
Atherogenic forms of dyslipidemia in women with polycystic ovary syndrome 120
Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group 119
Does metformin induce ovulation in normoandrogenic anovulatory women? 117
Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes 117
The spectrum of androgen excess disorders 115
Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. 113
Evidence for altered adipocyte function in polycystic ovary syndrome 111
Assessment of cardiovascular risk and prevention of cardiovascular disease in women with Polycystic Ovary Syndrome: a consensus statement of the Androgen Excess and PCOS (AE-PCOS) Society 110
Introduction to the special issue: 2012 AE-PCOS meeting 110
Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome 109
Need for liver evaluation in polycystic ovary syndrome 109
Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women 108
Correlates of increased lean muscle mass in women with polycystic ovary syndrome 107
Androgen excess and cardiovascular risk. 105
Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome 105
The importance of diagnosing the Polycystic Ovary Syndrome 103
The malnutrition in the elderly: a clinical approach. 102
Uterine effects of metformin administration in anovulatory women with polycystic ovary sindrome 98
Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk factors 97
The diagnosis of polycystic ovary syndrome in adolescents 96
-Correlation between deficiency of 25 (OH) vitamin D and liver damage in adult talassemic subjects 93
Bone turnover markers in postmenopausal womens treated with alendronate or risedronate: differences in early dynamics 90
Not all women diagnosed with PCOS share the same cardiovascular risk profiles 90
Increasing adiposity in normal ovulatory women affects adipocytokine expression in subcutaneous and visceral abdominal fat 88
Correlation between deficienty of 25 (oh) vitamin D and liver damage in adult talassemic subjects 85
Obesity, Adipokines and Metabolic Syndrome in Polycystic Ovary Syndrome 85
Correlation between deficiency of 25 (OH)-vitamin D, bone mineral density and markers of bone turnover in sicilian postmenopausal womens 84
How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? 82
Ovarian size and blood flow in women with polycystic ovary syndrome (PCOS) and their correlations with some endocrine parameters 81
Elevated levels of non-HDL-cholesterol are relatively uncommon in women with PCOS and generally reflect LDL-cholesterol levels. 81
Non-classic forms of atherogenic dyslipidemia in women with polycystic ovary syndrome. 80
Long-term consequences of polycystic ovary syndrome on cardiovascular risk 80
Position statement: criteria for defining Polycystic Ovary Syndrome as predominantly hyperandrogenic syndrome: an androgen excess society guideline 79
Mullarian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin-B 76
Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines 76
Body composition of individuals with polycystic ovary syndrome 76
When periods stop: cardiovascular consequences of PCOS. 75
Editorial 74
Correlation between deficiency of 25 (OH) vitamin D, bone mineral density and markers of bone turnover in sicialian postmenopausal womens 73
Differences in early dynamics of serum bone markers in women with postmenopausal osteoporosiseated by alendronate or risedronate 70
Low circulating levels of HDL-cholesterol in women with PCOS and no other lipid abnormalities are associated to increased carotid intima media thickness and finding of atherogenic plaques. 70
Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. 70
Role of hypogonadism in development of bone alterations in thalassemic patients 69
Statins and osteoporosis: myth or reality? 67
Birth weight in polycystic ovary syndrome: correlation with adult insulin sensitivity. 65
Fat distribution in idiopathic hyperandrogenism. 64
Differences in early dynamics of serum bone markers in women with postmenopausal osteoporosis treated by alendronate or risedronate 62
Estroprogestins and cardiovascular risk in Polycystic Ovary Syndrome 62
Metabolic Syndrome in Polycystic Ovary Syndrome 61
Endothelial abnormalities in young women with PCOS: correlations with insulin resistance and decreased levels of serum adiponectin 61
Milder forms of atherogenic dyslipidemia in ovulatory vs. anovulatory polycystic ovary syndrome phenotype. 60
Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype 58
In PCOS women AMH circulating levels predict patients who become ovulatory with aging. 50
PCOS: metabolic impact and long-term management 50
La somministrazione di amfotericina B per via endoarteriosa rappresenta una valida e sicura terapia della mucormicosi 36
Totale 7.759
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.377
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.377
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.264 0 0 0 0 0 304 250 146 249 81 139 95
2020/20211.036 45 124 59 104 107 63 88 64 120 68 87 107
2021/2022852 29 246 13 22 26 26 61 39 86 82 55 167
2022/2023991 116 224 13 101 126 151 15 81 114 5 38 7
2023/2024388 14 80 27 88 37 70 25 13 1 8 5 20
2024/2025458 30 139 91 127 50 21 0 0 0 0 0 0
Totale 7.759